← ANALYST RATINGS · TIPRANKS
Agios Pharma (AGIO): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy1 Hold0 Sell
Ratings of 3 analysts in the last 3 months · top analysts only12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $34.50, the highest $37.00, the lowest $32.00. The average is +10.2% from the last price of $31.32.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $35.00 → $32.00−8.6% | Hold | +2.2% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $34.00 → $31.00−8.8% | Hold | −1.0% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $34.00 → $31.00−8.8% | Hold | −1.0% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $33.00 → $30.00−9.1% | Hold | −4.2% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $35.00 → $32.00−8.6% | Hold | +2.2% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $33.00 → $30.00−9.1% | Hold | −4.2% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $32.00 | Hold | +2.2% | Reiterated | 08.10.26on TipRanks 21:45 | −0.9%next day −3.1% · 5 days +0.4% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | $39.00 → $37.00−5.1% | Buy | +18.1% | Reiterated | 07.10.26on TipRanks 09:10 | +0.5%next day +0.8% · 5 days −1.6% | ↗ |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | $50.00 | Buy | +59.6% | Reiterated | 06.10.26on TipRanks 06:35 | +1.0%next day +0.5% · 5 days −4.6% | ↗ |
| Marc Frahm★★★★★★★★★★#223 · hits 56% · avg +25.8% | TD Cowen | — | Buy | — | Reiterated | 03.08.26on TipRanks Aug 4 01:30 | +0.3%next day +1.7% · 5 days +4.7% | ↗ |
| Samantha Semenkow★★★★★★★★★★#6889 · hits 47% · avg +0.7% | Citi | $46.00 → $52.00+13.0% | Buy | +66.0% | Reiterated | 31.07.26on TipRanks 06:41 | −9.1%next day +0.3% · 5 days +4.0% | ↗ |
| Emily Bodnar★★★★★★★★★★#2140 · hits 39% · avg +7.2% | H.C. Wainwright | $52.00 → $55.00+5.8% | Buy | +75.6% | Reiterated | 30.07.26on TipRanks 13:18 | −8.1%next day −9.1% · 5 days −6.1% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $32.00 | Hold | +2.2% | Reiterated | 21.07.26on TipRanks Jul 27 06:42 | −7.6%next day −3.4% · 5 days −2.7% | ↗ |
| Andrew Berens★★★★★★★★★★#336 · hits 49% · avg +24.7% | Leerink Partners | — | Buy | — | Reiterated | 07.07.26on TipRanks 11:45 | +18.2%next day −2.5% · 5 days −9.8% | ↗ |
| Tessa Romero★★★★★★★★★★#805 · hits 57% · avg +21.7% | J.P. Morgan | $36.00 → $31.00−13.9% | Hold | −1.0% | Assigned | 11.06.26on TipRanks Jun 10 19:25 | −2.3%next day +2.0% · 5 days +17.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Agios Pharma
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $44.20 at a price of $33.25 (+32.9%); now: $43.00 at $31.32 (+37.3%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 6 | 10 | 10 | 11 | 7 | 3 |
| Hold | 4 | 7 | 5 | 4 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.24 (from $-1.58 to $-1.06). Last quarter: $-1.69.
Sales
Next quarter’s sales estimate — $52M (from $47M to $55M). Last quarter: $45M.
Best top-analyst consensus in the sector · Healthcare
About Agios Pharma
- CEO: Brian Goff
- Employees: 540
- 88 Sidney Street, Cambridge, MA, 02139, US
- www.agios.com
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Data from the stock’s TipRanks forecast page, read 99 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗